Shawn Singh, CEO of VistaGen Therapeutics discusses their pipeline which includes nasal sprays that work like spritzers to the brain, for instance, PH10, an experimental antidepressant that completed a phase 2a study and received a patent and PH94B for Social Anxiety Disorder.
Shawn Singh has served as VistaGen’s CEO since August 2009 and on its Board of Directors since 2000. Mr. Singh has over 25 years of experience working with private and public biotechnology, medical device, and pharmaceutical companies, a venture capital firm and contract research and development organization (CRO), serving in numerous senior management roles. Prior to joining VistaGen, Mr. Singh served as Managing Principal of Cato BioVentures, a healthcare-focused VC firm, and as Chief Business Officer and General Counsel of Cato Research Ltd, a global CRO affiliated with Cato BioVentures. Earlier, Mr. Singh served as Chief Business Officer of SciClone Pharmaceuticals (NASDAQ: SCLN), a U.S.-based, China-focused specialty pharmaceutical company. He began his career as a corporate finance attorney in the Silicon Valley offices of Morrison & Foerster, an international law firm. Mr. Singh earned a B.A. degree, with honors, from the University of California, Berkeley, and J.D. degree from the University of Maryland School of Law. He is a member of the State Bar of California.